ECM
FOLD

ExodusPoint Capital Management’s Amicus Therapeutics FOLD Stock Holding History

ExodusPoint Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.54M Buy
244,838
+163,370
+201% +$2.34M 0.03% 551
2025
Q4 		$1.16M Sell
81,468
-41,906
-34% -$412K 0.01% 936
2025
Q3 		$972K Buy
+123,374
New +$878K 0.01% 969
2025
Q2 		– Sell
-332,207
Closed -$2.71M – 1620
2025
Q1 		$2.71M Buy
332,207
+53,138
+19% +$492K 0.03% 594
2024
Q4 		$2.63M Sell
279,069
-537,938
-66% -$5.59M 0.02% 620
2024
Q3 		$8.73M Buy
817,007
+35,490
+5% +$387K 0.05% 260
2024
Q2 		$7.75M Buy
781,517
+138,132
+21% +$1.42M 0.05% 304
2024
Q1 		$7.58M Buy
643,385
+271,005
+73% +$3.47M 0.06% 266
2023
Q4 		$5.28M Sell
372,380
-569,053
-60% -$6.46M 0.03% 330
2023
Q3 		$11.4M Buy
941,433
+317,580
+51% +$4.1M 0.11% 198
2023
Q2 		$7.84M Buy
623,853
+468,018
+300% +$5.55M 0.06% 306
2023
Q1 		$1.73M Buy
155,835
+40,044
+35% +$494K 0.01% 943
2022
Q4 		$1.41M Sell
115,791
-177,189
-60% -$1.99M 0.02% 795
2022
Q3 		$3.06M Buy
292,980
+163,746
+127% +$1.82M 0.04% 584
2022
Q2 		$1.39M Buy
+129,234
New +$1.06M 0.02% 942
2022
Q1 		– Sell
-20,758
Closed -$240K – 2336
2021
Q4 		$240K Sell
20,758
-177,013
-90% -$1.97M ﹤0.01% 1745
2021
Q3 		$1.89M Buy
197,771
+109,376
+124% +$1.12M 0.03% 745
2021
Q2 		$852K Sell
88,395
-2,942
-3% -$28.7K 0.01% 1082
2021
Q1 		$902K Buy
91,337
+10,147
+12% +$157K 0.01% 981
2020
Q4 		$1.88M Sell
81,190
-25,326
-24% -$518K 0.02% 562
2020
Q3 		$1.5M Buy
+106,516
New +$1.55M 0.03% 502
2020
Q1 		– Sell
-46,457
Closed -$452K – 1260
2019
Q4 		$452K Buy
46,457
+23,757
+105% +$217K 0.01% 915
2019
Q3 		$182K Buy
+22,700
New +$246K 0.01% 1149

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

ExodusPoint Capital Management's FOLD Position: Q1 2026 in Review

ExodusPoint Capital Management increased its Amicus Therapeutics (FOLD) stake by 201% in Q1 2026, buying an estimated $2.34M and bringing the position to 244,838 shares worth $3.54M. The position accounts for 0.03% of the portfolio, ranked #551.

ExodusPoint Capital Management first reported a position in FOLD in Q3 2019 and has held it in 23 quarters since. The position peaked at $11.4M in Q3 2023. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • ExodusPoint Capital Management held 244,838 shares of Amicus Therapeutics worth $3.54M as of Q1 2026.
  • ExodusPoint Capital Management bought 163,370 Amicus Therapeutics shares in Q1 2026, an estimated $2.34M.
  • Amicus Therapeutics made up 0.03% of ExodusPoint Capital Management's portfolio in Q1 2026, its #551 holding.
  • ExodusPoint Capital Management first reported a position in Amicus Therapeutics in Q3 2019 and has held it in 23 quarters since.
  • ExodusPoint Capital Management's Amicus Therapeutics position peaked at $11.4M in Q3 2023.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.